Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.

05/20/2026, 9:50 AM • Benzinga

Scalable Biotech Manufacturing Unlocks a $14B Market

The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.

03/27/2026, 9:15 AM • Benzinga

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.

03/03/2026, 10:02 AM • Benzinga

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The iPSC-derived NK cells clinical trial pipeline is experiencing significant momentum with 12+ companies developing 15+ pipeline therapies. Key players including Century Therapeutics, Fate Therapeutics, Cartherics, and others are advancing promising candidates like CNTY-101, FT522, and CTH-401 across various clinical stages. Recent developments include Century's CNTY-101 continuation in Phase I/II trials and Fate's positive initial data from FT522 in relapsed/refractory B-cell lymphoma, positioning iPSC-derived NK cells as a cornerstone of next-generation cancer immunotherapy.

02/16/2026, 1:00 PM • GlobeNewswire

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

01/23/2026, 12:56 PM • GlobeNewswire

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Fate Therapeutics reported promising initial clinical results for FT819, an off-the-shelf CAR T-cell therapy treating systemic lupus erythematosus, demonstrating significant disease activity reductions and potential for immune system remodeling with minimal conditioning chemotherapy.

10/26/2025, 11:30 AM • GlobeNewswire